Similarly, in cancer survivors, tested 6 months to 5 years after the end of the treatment, we found that (in addition to V ̇O2peak, TNF-α, age) fatigability explained 35% of the variance in cancer-related fatigue severity (30). The gene discussed is TNF; the disease is cancer.